Takeda Pharmaceutical (NYSE:TAK) Hits New 12-Month High – Still a Buy?

Shares of Takeda Pharmaceutical Co. (NYSE:TAK) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $18.82 and last traded at $18.7550, with a volume of 353110 shares traded. The stock had previously closed at $18.52.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on TAK shares. Morgan Stanley started coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. Wall Street Zen lowered shares of Takeda Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 21st. Finally, Zacks Research raised shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. One research analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Price Performance

The firm has a market cap of $59.97 billion, a PE ratio of 78.52 and a beta of 0.01. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56. The company has a 50 day moving average price of $17.91 and a 200 day moving average price of $15.81.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Friday, January 30th. The company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.07). The firm had revenue of $7.60 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Takeda Pharmaceutical had a net margin of 2.58% and a return on equity of 10.60%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.160-3.160 EPS. On average, sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Private Trust Co. NA boosted its position in shares of Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock worth $27,000 after buying an additional 783 shares in the last quarter. Twin Peaks Wealth Advisors LLC purchased a new position in Takeda Pharmaceutical during the 2nd quarter valued at about $28,000. True Wealth Design LLC increased its holdings in Takeda Pharmaceutical by 1,262.3% during the 3rd quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock valued at $40,000 after acquiring an additional 2,512 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after acquiring an additional 1,684 shares during the last quarter. Finally, SHP Wealth Management acquired a new position in Takeda Pharmaceutical during the fourth quarter worth about $42,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.